ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it...
3 KB (180 words) - 08:12, 24 September 2024
Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021. "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects". ClinicalTrials...
95 KB (18,965 words) - 23:35, 15 September 2024
DelNS1-2019-nCoV-RBD-OPT GRAd-COV2 ImmunityBio iNCOVACC INNA-051 NDV-HXP-S Vaxart COVID-19 vaccine Virus-like particles ABNCoV2 LYB001 MigVax-101 VBI-2902...
180 KB (23,898 words) - 14:59, 19 August 2024